Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells

被引:40
作者
Kreppel, M
Aryee, DNT
Schaefer, KL
Amann, G
Kofler, R
Poremba, C
Kovar, H
机构
[1] Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany
[2] Med Univ Vienna, Inst Pathol, Vienna, Austria
[3] Tyrolean Canc Res Inst, Innsbruck, Austria
基金
奥地利科学基金会;
关键词
Ewing's sarcoma; EWS-FL11; CD99; migration; ion channels;
D O I
10.1038/sj.onc.1209300
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High CD99 expression levels and rearrangements of the EWS gene with ETS transcription factor genes characterize the Ewing's sarcoma family of tumors (ESFT). CD99 is a cell surface glycoprotein whose engagement has been implicated in cell proliferation as well as upregulation and transport of several transmembrane proteins in hematopoietic cells. In ESFT, antibody ligation of CD99 induces fast homotypic cell aggregation and cell death although its functional role in these processes remains largely unknown. Here, using an RNAi approach, we studied for the first time the consequences of modulated CD99 expression in six different ESFT cell lines, representing the most frequent variant forms of EWS gene rearrangement. CD99 suppression resulted in growth inhibition and reduced migration of ESFT cells. Among genes whose expression changes in response to CD99 modulation, the potassium-channel modulatory factor KCMF1 was consistently upregulated. In a series of 22 primary ESFT, KCMF1 expression levels inversely correlated with CD99 abundancy. Cells forced to express ectopic KCMF1 showed a similar reduction in migratory ability as CD99 silenced ESFT cells. Our results suggest that in ESFT, high CD99 expression levels contribute to the malignant properties of ESFT by promoting growth and migration of tumor cells and identify KCMF1 as a potential metastasis suppressor gene downregulated by high constitutive CD99 expression in ESFT.
引用
收藏
页码:2795 / 2800
页数:6
相关论文
共 32 条
[1]   CD99 isoform expression dictates T-cell functional outcomes [J].
Alberti, I ;
Bernard, G ;
Rouquette-Jadanian, AK ;
Pelassy, C ;
Pourtein, M ;
Aussel, C ;
Bernard, A .
FASEB JOURNAL, 2002, 16 (12) :1946-+
[2]  
AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO
[3]  
2-U
[4]   Biology of EWS/ETS fusions in Ewing's family tumors [J].
Arvand, A ;
Denny, CT .
ONCOGENE, 2001, 20 (40) :5747-5754
[5]  
Bernard G, 1997, J IMMUNOL, V158, P2543
[6]  
BERNARD G, 1995, J IMMUNOL, V154, P26
[7]   Identification of CBFA1-regulated genes on SaOs-2 cells [J].
Bertaux, K ;
Broux, O ;
Chauveau, C ;
Jeanfils, J ;
Devedjian, JC .
JOURNAL OF BONE AND MINERAL METABOLISM, 2005, 23 (02) :114-122
[8]   Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators [J].
Cerisano, V ;
Aalto, Y ;
Perdichizzi, S ;
Bernard, G ;
Manara, MC ;
Benini, S ;
Cenacchi, G ;
Preda, P ;
Lattanzi, G ;
Nagy, B ;
Knuutila, S ;
Colombo, MP ;
Bernard, A ;
Picci, P ;
Scotlandi, K .
ONCOGENE, 2004, 23 (33) :5664-5674
[9]  
Choi FY, 1998, J IMMUNOL, V161, P749
[10]  
Conti DJ, 2004, AM J TRANSPLANT, V4, P166